U.S. markets close in 3 hours 49 minutes
  • S&P 500

    3,900.93
    +89.78 (+2.36%)
     
  • Dow 30

    31,593.59
    +661.22 (+2.14%)
     
  • Nasdaq

    13,527.96
    +335.61 (+2.54%)
     
  • Russell 2000

    2,265.61
    +64.56 (+2.93%)
     
  • Crude Oil

    61.55
    +0.05 (+0.08%)
     
  • Gold

    1,731.60
    +2.80 (+0.16%)
     
  • Silver

    26.94
    +0.50 (+1.89%)
     
  • EUR/USD

    1.2060
    -0.0028 (-0.23%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • GBP/USD

    1.3943
    +0.0020 (+0.14%)
     
  • USD/JPY

    106.6500
    +0.1480 (+0.14%)
     
  • BTC-USD

    49,047.73
    +5,273.74 (+12.05%)
     
  • CMC Crypto 200

    981.62
    +53.38 (+5.75%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Pacific Biosciences of California, Inc. PACB recently announced the addition of the PacBio Sequel II System to inqaba biotec’s portfolio of genomics services.

inqaba biotec is the leading provider of a full range of DNA sequencing and DNA synthesis services. Pacific Biosciences has partnered with inqaba biotec to establish the latter as its first Sequel II System service provider for the entire Africa.

This development is expected to boost Pacific Biosciences’ flagship platform – the Sequel system.

More on the PacBio Sequel II System

Built on the well-established Single Molecule, Real-Time (SMRT) Sequencing technology, the Sequel II System offers highly precise long reads, with 15 times more data compared with the original Sequel System.

The PacBio Sequel II System is proficient at comprehensive variant detection, from single base changes to multi-kilobase structural variants, and can be used for a wide array of applications, including whole-genome, amplicon, and full-length transcriptome sequencing, as well as epigenetic characterization. With longer HiFi reads and higher throughput, the Sequel II System will help inqaba biotec collect not only human genomes but also those of plants and animals found in the African continent.

 

Customers can expect significant reduction in project costs and higher output from this system. Using data from the Sequel II System, highly accurate ethnic-specific human genome datasets can be generated that should enhance understanding of population genetics and disease response.

Recent Development

In April, the company announced collaborations with commercial, academic and government research teams that are studying the SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The highly detailed long reads produced by the company’s  SMRT Sequencing technology can be utilized in  solving variants of the virus that exist within a single individual or across a population of patients.

Market Prospect

Per a report by AlliedMarketResearch, the global DNA sequencing market was valued at $6.24 billion in 2017 and is projected to reach $25.47 billion in 2025, at a CAGR of 19.0%. Hence, this integration comes at an ideal time.

Price Performance

In the past three months, the stock has lost 35.8% compared with 7.9% decline of its industry.

Zacks Rank and Other Key Picks

Pacific Biosciences currently has a Zacks Rank # 2 (Buy).

Some other top-ranked stocks from the broader medical space are ResMed Inc. RMD, DexCom DXCM and Surmodics SRDX.

ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently carries a Zacks Rank #2.

Surmodics’ long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DexCom, Inc. (DXCM) : Free Stock Analysis Report
 
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research